
Lirafugratinib + LITESPARK011
OncoPharm
00:00
Quality Of Life Does Not Improve
John Bazar reviews patient-reported outcomes showing no significant quality-of-life advantage for lenvatinib plus belzutifan over cabozantinib.
Play episode from 12:32
Transcript


